Technology | 2019.10.22
DermBiont Announces Positive Data from Phase 2a Clinical Trial and Start of Phase 2b Clinical Trial for Athlete’s Foot with a Topical Live Biotherapeutic
DermBiont, a clinical stage microbiome biotechnology company developing topical live biotherapeutics, has announced that its lead program, DBI-001, met its primary safety endpoints, with no application site reactions and no adverse events, in a 12 person open labeled phase 2a clinical trial for the treatment of interdigital tinea pedis (athlete’s foot). Additionally, the trial demonstrated a clinical response with improvement in the signs and symptoms of tinea pedis and demonstrated a reduction in the abundance of Trichophyton rubrum.
(PRWeb October 22, 2019)
Read the full story at https://www.prweb.com/releases/dermbiont_announces_positive_data_from_phase_2a_clinical_trial_and_start_of_phase_2b_clinical_trial_for_athletes_foot_with_a_topical_live_biotherapeutic/prweb16632514.htm
For more information, please visit
https://www.prweb.com/releases/dermbiont[...]otherapeutic/prweb16632514.htm
